Note 14 - Segments (Tables)

3 Months Ended

Mar. 31, 2023

Three Months Ended March 31, 2023	Diagnostics			Therapeutics			Corporate			Total
Research and development expenses	$	1,170,553		$	96,900		$	—		$	1,267,453
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾		—			2,178			1,125,183			1,127,361
Depreciation and amortization ⁽²⁾		9,275			—			18,280			27,555
Loss from operations ⁽³⁾		(1,179,828	)		(99,078	)		(1,143,463	)		(2,422,369	)
Other expense ⁽⁴⁾		—			—			946,039			946,039
Net loss		(1,179,828	)		(90,078	)		(197,424	)		(1,476,330	)
Total assets, net of depreciation and amortization:
United States	$	—		$	—		$	1,776,386		$	1,776,386
International		578,272			—			12,928			591,200
Capital expenditures		15,068			—			—			15,068

Three Months Ended March 31, 2022	Diagnostics			Therapeutics			Corporate			Total
Research and development expenses	$	989,887		$	179,367		$	—		$	1,169,254
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾		—			—			1,787,152			1,787,152
Depreciation and amortization ⁽²⁾		6,040			—			16,838			22,878
Loss from operations ⁽³⁾		(995,927	)		(179,367	)		(1,803,990	)		(2,979,284	)
Other expense ⁽⁴⁾		—			—			(7,961	)		(7,961	)
Net loss		(995,927	)		(179,367	)		(1,811,951	)		(2,987,245	)
Total assets, net of depreciation and amortization:
United States	$	150,920		$	—		$	3,034,316		$	3,185,236
International		393,753			—			23,136			416,889
Capital expenditures		40,221			—			1,796			42,017